Tuesday, May 30, 2023


Biotechnology News Magazine

Sense Biodetection Expands Leadership Team

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Sense Biodetection innovator in the emerging field of instrument-free molecular diagnostics, has announced the appointment of Simon Turner as Chief Financial Officer and Ryan Roberts as Chief Commercial Officer.

Simon Turner, a veteran international finance and operations leader, joins Sense from Savran Technologies where he was CFO / COO. He has over 20 years’ experience in the diagnostics industry, including 10 years at Oxford Immunotec where he supported the company from early-stage R&D through successful commercial launch, global expansion, and IPO. He is an alumnus of Imperial College London and London Business School.

Roberts brings a diverse executive leadership background including device, software and services in both acute and post- and sub-acute medicine. Among his previous positions, Ryan was CCO at point of care diagnostics company Astute Medical prior to its acquisition by bioMérieux. He joins Sense from Edwards Life Sciences where he was VP Sales, US Critical Care. He is a graduate of the University of Notre Dame and Northwestern’s Kellogg School of Business.

Harry Lamble, CEO said, “I am thrilled to attract talent of Ryan’s and Simon’s caliber to our leadership team. Their experience will be invaluable as we launch our Veros COVID-19 test, the first of our portfolio of innovative molecular testing products that will help make decentralized healthcare a reality.”

Ryan Roberts, CCO commented, “Sense’s Veros products will bring the superior performance of molecular diagnostics closer to the patient to speed diagnosis, improve treatment decisions, and help protect patients’ loved ones and community. I look forward to working with the Sense team to bring our unique tests into the hands of users across the world.”

In conjunction with the rapid growth of its leadership team, Sense has completed commissioning of a substantial new distribution hub near Boston, MA, to support US launch of its Veros COVID-19 test.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine